Why did Quest raise revenue guidance but lower the low end of reported EPS guidance?

Quest raised its net revenue outlook to $10.80–$10.92 billion from $10.70–$10.85 billion, reflecting strong Q2 growth and continued utilization trends. The reported diluted EPS range moved to $8.60–$8.80 from $8.62–$8.87. The filing does not give a detailed explanation for the change. The adjusted EPS range was raised to $9.63–$9.83, so the reported range change appears tied to items excluded from adjusted results, such as special items, amortization, and the other gains recognized in 2025.

How much of the Q2 earnings growth came from one-time items?

Reported diluted EPS of $2.47 included a $46 million pre-tax gain from a CARES Act payroll tax credit, which contributed about $0.30 per share after tax. Adjusted EPS of $2.62, which removes this gain along with restructuring, amortization, and other items, grew 11.5%, a more conservative measure of underlying growth than the 21.7% reported figure.

How much of the revenue growth was organic versus acquired?

Of the 15.2% increase in Q2 net revenues, 5.2% was organic. The remainder came from acquisitions. Organic requisition volume grew 2.1% versus total requisition volume growth of 16.3%, and revenue per requisition declined 0.4%. Management cited expanded business from enterprise accounts and demand for clinical solutions as organic drivers.

What is the company's financial position after the recent debt activity?

Total debt, including current portion, was approximately $5.67 billion at June 30, 2025, down from about $6.22 billion at year-end 2024, after $1.0 billion in repayments partly offset by $400 million in new borrowings. Cash fell to $319 million from $549 million. Quarterly interest expense rose to $67 million from $44 million, so the company's higher borrowing costs are a key factor for investors to watch. Stockholders' equity increased to $7.27 billion from $6.81 billion.

Are there any notable risks or one-time items investors should consider?

The Q2 results included a $24 million impairment charge on long-lived assets tied to the potential exit of a business, and about $12 million of charges linked to contingent consideration from prior acquisitions for the full year. Restructuring and integration charges totaled $37 million estimated for 2025. The company also flagged risks including volatile economic conditions, government investigations and lawsuits, reimbursement complexity, and changes in government policy, including trade-related policy.

DGX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 22, 2025. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) reported strong second quarter 2025 results on July 22, 2025, with net revenues of $2.76 billion^a, up 15.2% year over year.

Organic revenue growth was 5.2%, and the balance of the increase came from acquisitions. Reported diluted EPS was $2.47^b, up 21.7%, while adjusted diluted EPS was $2.62, up 11.5%. Operating income rose 23.3% to $438 million, and operating margin expanded to 15.9% from 14.8%.

Year-to-date cash from operations reached $858 million^c, up 67.1%, supported by working capital and other operating asset and liability changes. Management raised full-year 2025 guidance. Net revenues are now expected at $10.80–$10.92 billion (9.4%–10.6% growth), up from $10.70–$10.85 billion.

Reported diluted EPS is now $8.60^d–$8.80, narrowed and slightly lower at the low end than the prior $8.62–$8.87 range, while adjusted diluted EPS rose to $9.63–$9.83 from $9.55–$9.80. Operating cash flow guidance was increased to approximately $1.55 billion from $1.5 billion, and capital expenditures remain at about $500 million. Quality of earnings warrants attention.

Q2 reported EPS benefited from a $46 million pre-tax CARES Act payroll tax credit gain, which is excluded from adjusted results. Interest expense rose to $67 million from $44 million, reflecting higher debt following acquisitions, and the company's cash balance fell to $319 million from $549 million at year-end 2024 after debt repayments. Revenue per requisition declined 0.4%, and growth in requisition volume (16.3%) was largely acquisition-driven, with organic requisition volume growing only 2.1%.

02—Key points

Key Highlights

Q2 2025 net revenues of $2.76 billion, up 15.2% year over year, including 5.2% organic growth; diagnostic information services revenues rose 15.7% to $2.70 billion.
Reported diluted EPS of $2.47 (up 21.7%) and adjusted diluted EPS of $2.62 (up 11.5%); the reported figure includes a $46 million pre-tax CARES Act payroll tax credit gain.
Operating margin improved to 15.9% reported (16.9% adjusted) from 14.8% a year earlier, with operating income up 23.3% to $438 million.
Full-year 2025 adjusted diluted EPS guidance raised to $9.63–$9.83 from $9.55–$9.80; net revenue guidance raised to $10.80–$10.92 billion.
Reported diluted EPS guidance was narrowed to $8.60–$8.80 from $8.62–$8.87, with a lower low end and a lower high end.
Year-to-date operating cash flow of $858 million, up 67.1%, and full-year operating cash flow guidance raised to approximately $1.55 billion from $1.5 billion.
Interest expense nearly doubled to $67 million in Q2 from $44 million, and cash fell to $319 million from $549 million at year-end 2024 after $1.0 billion in debt repayments year to date.

03—Questions

Frequently Asked Questions

Why did Quest raise revenue guidance but lower the low end of reported EPS guidance?
Quest raised its net revenue outlook to $10.80–$10.92 billion from $10.70–$10.85 billion, reflecting strong Q2 growth and continued utilization trends. The reported diluted EPS range moved to $8.60–$8.80 from $8.62–$8.87. The filing does not give a detailed explanation for the change. The adjusted EPS range was raised to $9.63–$9.83, so the reported range change appears tied to items excluded from adjusted results, such as special items, amortization, and the other gains recognized in 2025.
How much of the Q2 earnings growth came from one-time items?
Reported diluted EPS of $2.47 included a $46 million pre-tax gain from a CARES Act payroll tax credit, which contributed about $0.30 per share after tax. Adjusted EPS of $2.62, which removes this gain along with restructuring, amortization, and other items, grew 11.5%, a more conservative measure of underlying growth than the 21.7% reported figure.
How much of the revenue growth was organic versus acquired?
Of the 15.2% increase in Q2 net revenues, 5.2% was organic. The remainder came from acquisitions. Organic requisition volume grew 2.1% versus total requisition volume growth of 16.3%, and revenue per requisition declined 0.4%. Management cited expanded business from enterprise accounts and demand for clinical solutions as organic drivers.
What is the company's financial position after the recent debt activity?
Total debt, including current portion, was approximately $5.67 billion at June 30, 2025, down from about $6.22 billion at year-end 2024, after $1.0 billion in repayments partly offset by $400 million in new borrowings. Cash fell to $319 million from $549 million. Quarterly interest expense rose to $67 million from $44 million, so the company's higher borrowing costs are a key factor for investors to watch. Stockholders' equity increased to $7.27 billion from $6.81 billion.
Are there any notable risks or one-time items investors should consider?
The Q2 results included a $24 million impairment charge on long-lived assets tied to the potential exit of a business, and about $12 million of charges linked to contingent consideration from prior acquisitions for the full year. Restructuring and integration charges totaled $37 million estimated for 2025. The company also flagged risks including volatile economic conditions, government investigations and lawsuits, reimbursement complexity, and changes in government policy, including trade-related policy.

04—Continue

← View all 8-K filings